MINNEAPOLIS--(BUSINESS WIRE)--Medtronic (NYSE:MDT) announced today that results of a two-year follow-up study published in the December issue of the Archives of Otolaryngology–Head and Neck Surgery were favorable toward long-term use of Medtronic’s Meniett® Low-Pressure Pulse Generator for Ménière’s disease. The study concludes that approximately two-thirds of Ménière’s disease patients who are unresponsive to traditional medical treatment experience a significant, long-term reduction in vertigo frequency with Meniett therapy.
